TRIMTECH Therapeutics raises additional $14M in seed extension funding
What's the deal? TRIMTECH Therapeutics, a Cambridge, UK-based biotech, has raised an additional $14 million in seed extension funding to develop small molecule therapies for neurodegenerative diseases.
The round drew a deep bench of pharma backers, including Johnson & JohnsonDealroom has a profile for this one. Try Dealroom → Innovation – JJDC, BGF, Cambridge Innovation CapitalDealroom has a profile for this one. Try Dealroom →, the Dementia Discovery FundDealroom has a profile for this one. Try Dealroom →, M VenturesDealroom has a profile for this one. Try Dealroom →, PfizerDealroom has a profile for this one. Try Dealroom → Ventures , Eli Lilly and Company, MP Healthcare Venture ManagementDealroom has a profile for this one. Try Dealroom →, and Cambridge Enterprise Ventures.
The cash brings TRIMTECH's total seed funding to $47 million. It plans to use the money to expand operations and development efforts.
Why now? Founded in 2023, TRIMTECH is building "TRIMTAC" degraders that target and destroy the protein aggregates linked to diseases like Alzheimer's.
Its pitch: the degraders can break down harmful proteins while leaving the healthy functional form intact.
What could go wrong? The science is early-stage and unproven in humans. Neurodegenerative drug development is notoriously hard, with a long history of costly late-stage failures.
The signal: The presence of three Big Pharma corporate venture arms — J&J's JJDC, Pfizer Ventures, and Eli Lilly — alongside the specialist Dementia Discovery Fund points to deep industry conviction in TRIMTECH's degrader approach. For a company founded in 2023 and already at breakout stage with $47 million raised, that backing positions it as a notable bet in the high-stakes hunt for Alzheimer's therapies.
Read more: finsmes.com
Image credit: "Microscopic embryonic mouse brain (DAPI, GFP)" by CodonAUG is licensed under CC BY 2.0. To view a copy of this license, visit https://creativecommons.org/licenses/by/2.0/.
